NDAINTRAVITREALSOLUTIONPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IZERVAY (avacincaptad pegol) is a small-molecule intravitreal injection approved in August 2023 for retinal disease. It is a complement C5 inhibitor delivered directly to the eye as a solution. The drug represents a novel approach to treating retinal conditions by modulating local immune and inflammatory pathways.
$0.216MPart D
Growth8.1 years to LOEEarly-stage product with minimal current market penetration; significant runway for commercial team expansion and market development activities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
Started Jul 2025
20 enrolled
Geographic AtrophyAge-Related Macular Degeneration
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Started Jan 2025
500 enrolled
Geographic AtrophyMacular Degeneration
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
Started Sep 2022
278 enrolled
Geographic AtrophyAge-Related Macular Degeneration
A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration
Started Jul 2009
47 enrolled
Dry Age-Related Macular Degeneration
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
Started Oct 2008
60 enrolled
Neovascular Age-Related Macular Degeneration
Worked on IZERVAY at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.